NCT06140641Completed
Effects of the Bifidobacterium Longum BL21 on BMI, Metabolic Indicators, and Gut Microbiota in Overweight/Obese Adults
Effects of Supplementing the Bifidobacterium Longum BL21 on BMI, Metabolic Indicators, and Gut Microbiota in Overweight/Obese Adults: a Randomized, Double-blind, Placebo-controlled Trial
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
The goal of this study is to investigate the effects of Bifidobacterium longum subspecies BL21 on BMI, metabolic indicators, and changes in gut microenvironment microbiota in overweight/obese adults. The blood, urine, and feces samples of the subjects need to be collected at 0,4 and 8 week and promptly tested in the laboratory. During the intervention period, all groups of subjects were required to take the corresponding products daily and record adverse reactions.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 72 (actual)
- First submitted
- 7 Sept 2023
- Start date
- 29 Nov 2023
- Primary completion date
- 30 Jul 2024
- Lead sponsor
- Qilu Hospital of Shandong University
- Diseases
- Obesity
- NCT number
- NCT06140641
What you commit to
- Study type: Interventional
- Participants enrolled: 72
- From 29 Nov 2023 to the primary completion date, 30 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with serious chronic diseases (heart, liver, kidney, hematopoietic system, tumor and other serious diseases, mental disease and organ surgery history, diabetes, etc.) and complications;
- Patients with severe allergies and immune deficiencies;
- Patients with a clear history of gastrointestinal diseases (ulcers, irritable bowel syndrome, etc.);
- Have a history of intervention with lipid-lowering drugs or health products within the past 2 months;
- Failure to consume the test sample as required, or failure to follow up on time, resulting in uncertain efficacy
Other
- Pregnant, breastfeeding, or expectant women during the study period
- Individuals who have used antibiotics within the past two weeks;
- Subjects deemed unsuitable by other researchers to participate.
Who the study is looking for
- Body mass index (BMI) ≥ 24kg/m2 indicates overweight, and BMI ≥ 28kg/m2 indicates obesity;
- Willing to take the test formulation daily during the study period;
- Subjects who understand clinical research and commit to complying with research requirements and procedures.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Qilu hospital Coordinator of this site? Confirm its status | Jinnan | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.